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Abstract
Background: Cervical cancer, caused by persistent infection with carcinogenic human papillomavirus (HR-HPV), is
particularly prevalent in Sub-Saharan Africa and is associated with a high mortality rate. Some studies in West
Africa, including our own, have found unusually high HR-HPV across all ages with a slight peak in older women.
This increased prevalence at older ages may complicate screen-and-treat programs, which are implemented in
regions where HPV prevalence declines with age and typically target women between 30-49 years. A better
understanding of the determinants of high HR-HPV prevalence at older ages is needed. The goal of this study is to
explore risk factors for HR-HPV prevalence by age among women in our population-based study in Irun, a rural
town in southwestern Nigeria.
Methods: 1,420 women were administered a clinic-based questionnaire regarding sexual and reproductive
behavior, marital status (including co-wives), and malaria exposure. Logistic regression compared questionnaire
responses and PCR positivity for a set of 13 carcinogenic HR-HPV types. Results were stratified by age (15-29, 30-45,
46-55, and 56+ years).
Results: Birth control use and age at first pregnancy were associated with HR-HPV (p-value = 0.03 and 0.05,
respectively). Early age at sexual debut and multiple sex partners were risks for HR-HPV, but did not reach significance
(p-value = 0.1 and 0.07, respectively). Neither self-reported malaria nor presence of co-wives in the household was
associated with HR-HPV (p-value = 0.85 and 0.24, respectively). In age sub-categories, early age at sexual debut was a
significant risk factor for HR-HPV among women 35-45 years (p-value = 0.02). Early age at first pregnancy remained a
significant risk factor for women aged 56+ years (p-value = 0.04). Greater than 2 sex partners and use of birth control
were associated (though not significantly) with HR-HPV in women aged 30-45 (p-value = 0.08, respectively).
Conclusions: In this high-risk region with elevated HR-HPV prevalence at older ages, we confirmed previously
described, behavioral determinants of HR-HPV. There was no association with self-reported malaria or co-wives,
which we had hypothesized might correlate with HR-HPV at older ages.
Background
Cervical cancer, caused by persistent infection with car-
cinogenic human papillomavirus (HR-HPV), is the sec-
ond most common cancer in women worldwide and the
leading cause of cancer deaths among women in devel-
oping countries [1]. Cervical cancer is particularly
prevalent in Sub-Saharan Africa and is associated with a
high mortality rate [1-3]. Reasons for this increased pre-
valence are not completely understood, but likely
include limited access to medical care (especially in
rural areas) and lack of available or affordable treatment
options [4]. Other geographic and cultural risk factors
that are widespread in Sub-Saharan Africa include: early
marriage, polygamous marriages, and high parity.
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also endemic in this region [5,6].
The age-specific pattern of HR-HPV prevalence can
differ somewhat by geographic location. In most popula-
tions, incidence and prevalence of HR-HPV infection
peak at young ages soon after sexual debut, followed by
a decline as nearly all infections clear and new sexual
encounters decrease [7,8]. This pattern motivates the
use of HR-HPV screen-and-treat programs, targeted to
women past the peak age of HR-HPV prevalence.
However, high HR-HPV prevalence at all ages has
been reported in some, but not all, population-based
studies conducted in sub-Saharan Africa, including areas
of West Africa [9-11]. Recently, we have shown a similar
pattern from our population-based study in Irun, a rural
village in southwestern state of Ondo, Nigeria, where
the prevalence of HR-HPV even among cervical cytolo-
gically normal women appears to be consistently ele-
vated across all ages with a slight peak in older women
[12]. The reasons for the high HR-HPV prevalence at
older ages, which may negatively affect the performance
of HR-HPV screen-and-treat programs, are unknown.
Data on HR-HPV risk factors in among older women,
particularly in West Africa, are very limited [13-15].
Here we present a study examining clinic-based ques-
tionnaire data from approximately 1,400 women in our
population-based cohort in Irun, Nigeria. The goal of
this study was to evaluate the association between
known and possible, novel risk factors for HR-HPV
infection such as sexual and reproductive behaviors, liv-
ing in a household with co-wives, and self-reported
malaria exposure. Since we are particularly interested in
understanding the elevated HR-HPV prevalence among
older women in this region, we extended our analyses to
look at these risk factors among women of different age
groups.
Methods
The protocol was reviewed and approved by both Niger-
ian and NCI institutional review boards. Detailed meth-
odologic aspects of this study are described elsewhere
[12]. Briefly, households were surveyed based on a cen-
sus done by local health workers. All houses known to
have a household with co-wives as well as a random
sample of the remaining houses (439 total) were selected
to reach approximately 2,100 women. Women were
screened in their homes by a local health worker for
eligibility criteria (not pregnant, without a hysterectomy,
15+ years of age, lived in the house for more than three
months). A total of 2,091 women were deemed eligible
for enrollment. About one-third (n = 669) refused
enrollment either at home or did not show up for clinic.
Participation varied by age: women aged 15-20 years
were less likely to enroll and attend clinic visit (43.1%
vs. 74.3% among women over 20). A total of 1,422
women attended a clinic appointment.
A tt h ec l i n i cv i s i t ,w o m e nc o m p l e t e das e c o n d
informed consent and were given more detailed infor-
mation of clinic procedures. Following consent, 1,420
women were administered a questionnaire that
addressed potential risk factors associated with HR-HPV
and cervical pre-cancer such as tar and tobacco expo-
sure, number of malaria diagnoses within the past two
years, menstrual history, sexual behavior, marital status,
and birth control use. Nurses conducted a cervical exam
involving the collection of cervical cells using a broom
device and endocervical brush, and placed into Preserv-
Cyt buffer. On the day of collection, 1 ml was removed,
frozen, and subsequently used for the HR-HPV DNA
testing discussed here.
T h ep r e s e n c eo fH R - H P VD N Aw a sd e t e r m i n e df r o m
the 1 ml of residual cytology specimens using MY09-
MY11 PCR-based method as described [16]. We consid-
ered 13 HPV types to be carcinogenic types: 16, 18, 31,
33, 35, 39, 45, 51, 52, 56, 58, 59, and 68. Of 1,282 non-
virgins for whom HPV DNA test results were available,
14.7% were infected with one or more carcinogenic HR-
HPV genotypes [12].
Based upon previous age analysis of HR-HPV in this
population of women and taking menopausal status into
account [12], age categories were defined as follows: 15-
29 years (n = 300), 30-45 years (n = 452), 46-55 years (n
= 238) and 56+ years (n = 430). Logistic regression was
used to estimate odds ratios (ORs) and corresponding
95% confidence intervals (95% CI) for risk factors of
testing PCR positive for at least one of 13 carcinogenic
HR-HPV types among all women and stratified by age.
Questionnaire variables were categorized based on
observed trends in the data. P-values are reported as p-
trend when variables with more than two categories
were analyzed. To explore residual confounding by age,
within each age strata we adjusted for age in the logistic
regressions and did not find any significant differences.
To rule out the possibility that our findings were biased
by oversampling women who lived in houses containing
a household with more than one co-wife, we stratified
our results by co-wife status in the household (no co-
wife vs. one or more co-wives) and found no notable
differences. Analyses were performed using Stata 11.0
analytic software (Stata Corp LP, College Station, TX).
Results
The interviewers reported that the overall quality of the
interview was either generally reliable (75.8%) or of high
quality (22.2%). However, as shown in Figure 1, we
observed a tendency for women to respond with prefer-
ences for terminal digits, e.g., of ‘0’ or ‘5’ when reporting
their age. To verify the accuracy of our most important
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the standard IARC age categories [17] and by a more
agnostic age stratification in which women were
grouped according to the midpoint between digit prefer-
ences. Using these two different age categories, we
found slightly different HR-HPV prevalence curves
among younger women (Figure 1). We attribute this dif-
ference to the high HR-HPV prevalence among women
aged 25 years (36%). In contrast, the curve appeared
similar among older women.
Table 1 summarizes the clinical questionnaire data
and shows the relationship between these risk factors
and HR-HPV positivity. In terms of menstrual history,
most women (70%) reported age of menarche to be
between 15-19 years (average age 16.1 ± 2.5 years). The
majority of women reported an average age at sexual
Figure 1 Top: Graph showing preference for terminal digits 0 and 5 for self-reported age. Bottom: Percentage of women with high-risk
human papillomavirus (HR-HPV) shown using two different strategies for categorizing age. Abbreviations: IARC, International Agency for Research
on Cancer.
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partner in the last two years (~80%). The average age of
first pregnancy was 23.1 years and about 50% of women
reported having between 5-9 lifetime pregnancies (aver-
age number 6.5 ± 3.2 pregnancies). Only a small
percentage of women reported using birth control (14%)
and of those women very few responded as to what
type, although hormonal contraception appeared to be
the predominant method in comparison to condom use
(data not shown).
Table 1 Clinical questionnaire responses and potential risk factors for high risk human papillomavirus positivity
Total Positive for one or more HR-HPV genotypes
Categories n (%) n (%) OR 95% CI p-value
c
Age (yrs)
(mean = 45.2 ± 17, median = 45)
15 - 29 300 21.1 49 18.9 1.3 0.9 - 2.0
Mean = 45.2, median = 45 30 - 45 452 31.8 55 12.8 0.8 0.6 - 1.2
46 - 55 238 16.8 29 12.7 0.8 0.5 - 1.3
56+ 430 30.3 55 15.1 1.0 Ref 0.14
Age of Menarche (yrs) 10 - 14 224 17.6 33 16.1 1.0 0.6 - 1.8
Mean = 16.1, median = 15 15 - 19 891 70.0 119 14.6 0.9 0.6 - 1.5
20 - 25 158 12.4 22 15.9 1.0 Ref 0.83
Age at Sexual Debut (yrs) 10-14 47 3.5 12 25.5 2.4 1.1 - 5.3
Mean = 20.0, median = 20 15-24 1,059 79.7 148 14.8 1.2 0.8 - 2.0
25+ 223 16.8 23 12.2 1.0 Ref 0.10
Age at First Pregnancy (yrs) 12-19 178 14.4 27 16.2 1.4 0.9 - 2.4
Mean = 23.1, median = 23 20-24 523 42.4 84 17.1 1.5 1.1 - 2.2
25+ 534 43.2 56 11.8 1.0 Ref 0.05
Lifetime No. of Pregnancies 1 - 4 370 28.9 54 15.7 1.1 0.7 - 1.8
Mean = 6.5, median = 6 5 - 9 660 51.5 88 14.5 1.0 0.7 - 1.6
10+ 251 19.6 32 14.2 1.0 Ref 0.86
No. of Sex Partners (past 2 yrs) 2+ 311 23.1 54 18.2 1.4 1.0 - 2.0
Mean = 1.3, median = 1 1 1,034 76.9 131 13.9 1.0 Ref 0.07
Current Birth Control Use Yes 185 13.9 37 20.3 1.6 1.1 - 2.4
No 1,147 86.1 144 13.9 1.0 Ref 0.03
Current Marital Status
a Not in Union 450 33.5 66 16.4 1.2 0.9 - 1.7
In Union 895 66.5 117 13.9 1.0 Ref 0.25
In Household with Co-wives Yes 553 40.1 70 13.5 0.8 0.6 - 1.1 0.24
No 825 59.9 116 15.9 1.0 Ref
No. Other Wives 1 185 37.2 29 16.4 1.3 0.7 - 2.4
Mean = 2.1, median = 2 2 168 33.8 14 9.0 0.6 0.3 - 1.4
3+ 144 29.0 18 13.3 1.0 Ref 0.13
Rank Among Other Wives 1
st 222 45.0 26 12.4 1.3 0.6 - 2.9
Mean = 1.8, median = 2 2
nd 172 34.9 25 15.5 1.7 0.8 - 3.8
3
rd 99 20.1 9 9.8 1.0 Ref 0.40
Age of Youngest Wife (yrs) 15 - 29 42 13.9 8 19.1 0.7 0.2 - 2.2
Mean = 39.4, median = 40 30 - 59 236 78.1 25 11.4 0.4 0.1 - 1.0
60+ 24 8.0 6 26.1 1.0 Ref 0.11
Tobacco Exposure
b Yes 121 15.2 20 17.5 1.3 0.8 - 2.3
No 675 84.8 87 13.8 1.0 Ref 0.31
Number of Malaria Diagnoses (past 2 yrs) 3+ 453 35.2 64 15.5 1.1 0.6 - 2.1
2 371 28.9 45 13.4 0.9 0.5 - 1.8
Mean = 2.2, median = 2 1 355 27.6 43 13.7 0.9 0.5 - 1.8
0 107 8.3 14 14.3 1.0 Ref 0.85
a - In Union includes a woman who is either married or living with a man;
b- A“yes” response includes 77 women whose husbands smoke and 44 women who currently use tobacco
c - p-trend for variables with more than two response categories.
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majority of women were in union (either married or liv-
ing with a man) and about 60% of these women
reported that they resided in a household with co-wives,
reflecting the over-sampling in our field effort. A rela-
tively equal percentage reported having 1, 2, or 3+ co-
wives and 45% stated that they were ranked first among
other wives. This reflects that our recruitment efforts
were particularly successful among older women. The
average age of the youngest wife was 39.4 ± 10.7 years.
Most women reported that neither they nor their hus-
bands used tobacco, thus the overall exposure to
tobacco was relatively low (15.2%). A majority of women
reported having at least one case of malaria in the past
two years (average number of diagnoses 2.2 ± 1.5).
Overall, age was observed to be a risk factor, although
a non-linear one, for presence of HR-HPV, as we
observed an increased prevalence in women 15-29
(18.9%) and 56+ years (15.1%). An age of 10-14 years at
sexual debut was associated with a nearly two and a
half-fold risk for HR-HPV infection (OR 2.4; 95% CI
1.1-5.3) compared to late age. Early rather than late age
of first pregnancy was also associated with increased
HR-HPV prevalence with a 40% increased risk for ages
12-19 (OR 1.4; 95% CI 0.9-2.4) and a 50% increased risk
for ages 20-24 years (OR 1.5; 95% CI 1.1-2.2) compared
to late age. Having more than two sexual partners and
use of birth control were also positively related to HR-
HPV risk (OR 1.4; p-value = 0.07 and OR 1.6; p-value =
0.03).
With regard to our more novel hypothesized risk fac-
tors, we did not find associations of interest. Living in a
household with co-wives was associated with a slightly
decreased risk of HR-HPV positivity (OR 0.8; p-value =
0.24) although this relationship was not significant. The
number of self-reported malaria diagnoses in the past
two years was not associated with increased risk of HR-
HPV prevalence (p-value = 0.85).
Table 2 shows the distribution of key questionnaire
variables determined by the analyses above, including
t h o s et h a tw ef e l tt ob ei m p o r t a n tr i s kf a c t o r st o
explore, stratified by age. Women 15-29 years reported
younger ages at sexual debut and first pregnancy while
women 50+ years recalled the highest ages for these
measures. In addition, younger women were more likely
to have greater than two sex partners in comparison to
women aged 45-55 and 56+ years. The number of
women using birth control was highest among the 46-
55 year olds and lowest in women aged 56+ years.
Women 30 years or older were the most likely to be in
Table 2 Key clinical questionnaire responses stratified by age
15-29 Years 30-45 Years 46-55 Years 56+ Years p-value
a
n Row % n Row % n Row % n Row %
Age of Sexual Debut (yrs) < 0.01
10-14 20 7.7 19 4.4 7 3.1 1 0.3
15-24 235 90.7 379 87.9 174 77.7 274 66.0
25+ 4 1.6 33 7.7 43 19.2 140 33.7
Age First Pregnancy (yrs) < 0.01
12-19 73 38.0 57 13.4 28 12.7 20 5.1
20-24 105 54.7 219 51.3 80 36.4 119 30.0
25+ 14 7.3 151 35.4 112 50.9 257 64.9
No. Sex Partners (past 2 yrs) < 0.01
2+ 87 35.1 137 31.0 58 25.3 29 6.8
1 161 64.9 305 69.0 171 74.7 397 93.2
Current Birth Control Use < 0.01
Yes 34 12.7 86 19.9 48 21.2 17 4.2
No 233 87.3 346 80.1 178 78.8 390 95.8
In Household with Co-wives < 0.01
Yes 46 16.4 220 50.1 104 45.0 183 42.8
No 234 83.6 219 49.9 127 55.0 245 57.2
Number of Malaria Diagnoses
(past 2 yrs)
< 0.01
3+ 67 26.3 126 30.5 79 35.8 181 45.6
2 57 22.3 117 28.3 74 33.5 123 31.0
1 102 40.0 129 31.2 46 20.8 78 19.6
0 29 11.4 41 9.9 22 9.9 15 3.8
aFisher’s Exact test p-value.
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29 years did not live in a household with co-wives.
Interestingly, self-reportedm a l a r i aw a sm o s tp r e v a l e n t
in women aged 56+ years, who were more likely to
report three or more cases in the past 2 years and low-
est among women 15-29 years of age, who frequently
reported one or fewer cases.
Table 3 shows the risk of HR-HPV infection for table
2 variables within age strata. We had hypothesized that
the risk factors might help explain the high HR-HPV
prevalence at older ages. However, age stratification did
not reveal strong and consistent explanatory differences.
The slight differences are as follows: An age of 10-14
years at sexual debut was associated with a five-fold risk
for HR-HPV (10-14 years: OR 5.0; 15-24 years: OR 1.2;
p-trend = 0.02) in women aged 30-45 years. Early age at
first pregnancy was associated with a greater than two-
fold risk for HR-HPV in women aged 56+ years (12-19
years: OR 2.4; 20-24 years: OR 2.2; p-trend = 0.04).
Early age at sexual debut was also a risk factor among
women in this age group, although the association was
not quite as strong (15-24 years: OR 1.6; p-value =
0.15). Multiple sex partners and birth control use were
risk factors for women aged 30-45 (OR 1.7; p-value =
0.08 and OR 1.8; p-value = 0.8, respectively). Living in a
household with co-wives was not associated with HR-
HPV in this age stratified analysis. We did observe
somewhat of a dose response relationship with the num-
ber of recent self-reported malaria diagnoses and HR-
HPV prevalence in women aged 15-29 years, although
this relationship was not significant (p-trend = 0.31).
Discussion
The main goal of this study was to identify risk factors
for HR-HPV; particularly those associated with age that
would help to explain the increased prevalence of HR-
HPV infection among older women in this cohort.
Instead, among all women, we found expected beha-
vioral determinants of viral positivity, including early
age at sexual debut and multiple sex partners. Although
we did find that early age at sexual debut and first preg-
nancy were somewhat stronger risk factors among
women aged 30-45 and 56+ years, respectively, the
effects were not sufficiently different between the age
groups to explain the high HR-HPV prevalence older
women.
We hypothesized that being a co-wife might correlate
with HR-HPV appearance at older ages since a woman
in a polygamous marriage is theoretically engaged in
sexual relations with more than one partner; however
we did not observe this finding. We also hypothesized
that women with HR-HPV at older ages might be at
increased risk due to partial immunosuppression from
to chronics parasitosis, however there was no associa-
tion with recent self-reported malaria. Although self-
reported malaria exposure was not associated with risk
for HR-HPV infection, we did find an increase in recent
reported malaria cases among women aged 56+ years
compared to women in younger age groups. Even
though it was not related to HR-HPV, this is an inter-
esting finding given that prevailing research in endemic
areas indicates the highest malaria burden to be among
younger age groups [18,19]. It is possible that self-
reported malaria exposure is inaccurate, attenuating our
results. A recent study has shown that malaria self-
report data is highly sensitive and specific when preva-
lence is measured over a 6-month time frame, but that
specificity dramatically decreased when recalling after 18
and 30 months [20].
One important limitation of this study was the poten-
tial for selective response bias on our clinic question-
naire, particularly regarding questions related to sexual
and reproductive behavior as discussions of sexuality are
considered taboo among some Yoruba women [21,22].
The present study did not include HIV seroprevalence
data. However, we believe that HIV is unlikely to
explain the elevated HR-HPV prevalence in older
women. If anything, we would have expected HIV
immunosuppression to elevate HR-HPV prevalence at
earlier ages. We also did not have information on the
husband or partner’s sexual behavior and therefore addi-
tional confounding effects cannot be ruled out. The
cross-sectional nature of this study only permitted us to
look at HR-HPV prevalence and therefore we were not
able to evaluate risk factors for HR-HPV acquisition and
persistence.
Conclusions
The explanation for high HR-HPV prevalence at older
ages in rural Nigeria and other regions of Sub-Saharan
Africa remain elusive. Whether increased prevalence at
older ages is due to acquisition of new infections or to
attenuation in the immune response leading to a ree-
mergence of a latent infection remains unclear [7]. Data
from ongoing cohort studies have shown that the same
HR-HPV type can occasionally re-appear after apparent
clearance [23]. Our findings underscore the need for
enhanced knowledge about HR-HPV risk factors in
older women, as screening programs are not generally
targeted for this age group [12]. Future studies should
include more precise characterization of important
health determinants such as immune markers of malaria
exposure as well as more detailed information on male
sexual behavior [24]. Moving beyond questionnaire data,
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15-29 Years 30-45 Years 46-55 Years 56+ Years
n (%HR-HPV) OR 95% CI n (%HR-HPV) OR 95% CI n (%HR-HPV) OR 95% CI n (%HR-HPV) OR 95% CI
Age of Sexual Debut (years) 10-14 20 (25.0) 0.3 0.04 - 3.0 19 (36.8) 5.0 1.1 - 23.0 7 (0.0) N/A N/A 1 (0.0) N/A N/A
15-24 226 (18.1) 0.2 0.03 - 1.6 365 (11.8) 1.2 0.3 - 4.0 168 (13.1) 1.1 0.4 - 3.1 241 (17.4) 1.6 0.8 - 3.1
25+ 4 (50.0) 1.0 Ref 29 (10.3) 1.0 Ref 41 (12.2) 1.0 Ref 112 (11.6) 1.0 Ref
p-value
a = 0.29 p-value
a = 0.02 p-value
a = 0.90 p-value = 0.15
Age at First 12-19 70 (15.7) 0.5 0.1 - 1.8 53 (13.2) 1.5 0.6 - 3.9 27 (18.5) 1.4 0.5 - 4.3 17 (23.5) 2.4 0.7 - 8.1
Pregnancy 20-24 99 (22.2) 0.7 0.2 - 2.5 214 (15.0) 1.7 0.9 - 3.4 77 (10.4) 0.7 0.3 - 1.8 102 (21.6) 2.2 1.2 - 4.1
(years) 25+ 14 (28.6) 1.0 Ref 139 (9.4) 1.0 Ref 108 (13.9) 1.0 Ref 214 (11.2) 1.0 Ref
p-value
a = 0.42 p-value
a = 0.30 p-value
a = 0.54 p-value = 0.04
No. of Sex Partners (past two years) 2+ 84 (22.6) 1.4 0.7 - 2.7 132 (17.4) 1.7 1.0 - 3.0 56 (14.3) 1.1 0.5 - 2.7 25 (16.0) 1.1 0.4 - 3.2
1 154 (17.5) 1.0 Ref 289 (11.1) 1.0 Ref 165 (12.7) 1.0 Ref 336 (15.2) 1.0 Ref
p-value = 0.34 p-value = 0.08 p-value = 0.77 p-value = 0.91
Current Birth Control Use Yes 33 (27.3) 1.8 0.8 - 4.1 84 (19.1) 1.8 1.0 - 3.4 48 (16.7) 1.4 0.6 - 3.4 17 (23.5) 1.8 0.6 - 5.7
No 206 (17.5) 1.0 Ref 328 (11.6) 1.0 Ref 170 (12.4) 1.0 Ref 331 (14.8) 1.0 Ref
p-value = 0.19 p-value = 0.08 p-value = 0.45 p-value = 0.36
In Household with Co-wives Yes 43 (18.6) 0.9 0.4 - 2.2 211 (13.7) 1.1 0.6 - 2.0 100 (13.0) 1.0 0.4 - 2.2 163 (12.3) 0.7 0.4 - 1.2
No 200 (19.5) 1.0 Ref 208 (12.5) 1.0 Ref 121 (13.2) 1.0 Ref 200 (17.5) 1.0 Ref
p-value = 0.89 p-value = 0.71 p-value = 0.96 p-value = 0.16
Number of Malaria Diagnoses (past two years) 3+ 62 (21.0) 3.2 0.7 - 15.3 121 (15.7) 1.2 0.4 - 3.6 77 (11.7) 0.4 0.1 - 1.4 153 (15.0) 1.1 0.2 - 5.1
2 48 (22.9) 3.6 0.7 - 17.5 111 (8.1) 0.6 0.2 - 1.9 72 (11.1) 0.4 0.1 - 1.3 104 (16.4) 1.2 0.2 - 5.7
1 86 (16.3) 2.3 0.5 - 11.0 123 (12.2) 0.9 0.3 - 2.7 43 (11.6) 0.4 0.1 - 1.6 63 (14.3) 1.0 0.2 - 5.2
0 26 (7.7) 1.0 Ref 38 (13.2) 1.0 Ref 20 (25.0) 1.0 Ref 14 (14.3) 1.0 Ref
p-value
a = 0.31 p-value
a = 0.35 p-value
a = 0.47 p-value = 0.98
a - p-trend.
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8we are now pursuing serum-based studies of general
immunity and age-specificH R - H P Vp r e v a l e n c ei nt h e
Irun population.
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